An FDA advisory panel did not recommend a change in the agency’s outlook despite widespread atropine use in pediatric myopia, according to coverage of the Sydnexis data discussion. The panel instead leaned toward an additional trial to confirm a meaningful benefit, even as clinician support for approval has been reported. The review centered on establishing clinically significant improvement for the pediatric myopia indication and whether the available evidence meets a threshold for benefit. The panel’s stance reflects a conservative position on evidentiary standards, especially when real-world practice patterns—here, atropine use—do not substitute for trial outcomes. If FDA follows the advisory panel’s direction, it could extend development timelines for players pursuing pediatric myopia endpoints tied to regulator-defined benefit.